|
1
|
Online Mendelian Inheritance in Man (OMIM)
193300. BioPortal: Nov 18, 2019 (https://www.uniprot.org/database/DB-0062).
|
|
2
|
Ganeshan D, Menias CO, Pickhardt PJ,
Sandrasegaran K, Lubner MG, Ramalingam P and Bhalla S: Tumors in
von Hippel-Lindau syndrome: From head to toe-comprehensive
state-of-the-art review. Radiographics. 38:849–866. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chittiboina P and Lonser RR: von
Hippel-Lindau disease. In: Handbook of Clinical Neurology.
Elsevier, pp139-156, 2015.
|
|
4
|
Aronoff L, Malkin D, van Engelen K,
Gallinger B, Wasserman J, Kim RH, Villani A, Meyn MS and Druker H:
Evidence for genetic anticipation in vonHippel-Lindau syndrome. J
Med Genet. 55:395–402. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kruizinga RC, Sluiter WJ, de Vries EG,
Zonnenberg BA, Lips CJ, van der Horst-Schrivers AN, Walenkamp AM
and Links TP: Calculating optimal surveillance for detection of von
Hippel-Lindau-related manifestations. Endocr Relat Cancer.
21:63–71. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Palmer LS and Linehan WM: Editorial
comment. J Urol. 183:2351. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Iida K, Okimura Y, Takahashi K, Inomata S,
Iguchi G, Kaji H and Chihara K: A variety of phenotype with R161Q
germline mutation of the von Hippel-Lindau tumor suppressor gene in
Japanese kindred. Int J Mol Med. 13:401–404. 2004.PubMed/NCBI
|
|
8
|
Gong K, Zhang N, Zhang K and Na Y: The
relationship of erythropoietin overexpression with von
Hippel-Lindau tumour suppressor gene mutations between
hypoxia-inducible factor-1α and -2α in sporadic clear cell renal
carcinoma. Int J Mol Med. 26:907–912. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
David Dornbos 3III, Kim HJ, Butman JA and
Lonser RR: Review of the neurological implications of von
Hippel-Lindau disease. JAMA Neurol. 75:620–627. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Asthagiri AR, Mehta GU, Zach L, Li X,
Butman JA, Camphausen KA and Lonser RR: Prospective evaluation of
radiosurgery for hemangioblastomas in von Hippel-Lindau disease.
Neuro Oncol. 12:80–86. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lonser RR, Butman JA, Huntoon K, Asthagiri
AR, Wu T, Bakhtian KD, Chew EY, Zhuang Z, Linehan WM and Oldfield
EH: Prospective natural history study of central nervous system
hemangioblastomas in von Hippel-Lindau disease. J Neurosurg.
120:1055–1062. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nambu S, Otani R, Higuchi F, Uzuka T,
Matsuda H, Kim P and Ueki K: Histology of hemangioblastoma treated
with stereotactic radiosurgery confirms its effectiveness. J Clin
Neurosci. 51:43–45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim E and Zschiedrich S: Renal cell
carcinoma in von Hippel-Lindau disease-from tumor genetics to novel
therapeutic strategies. Front Pediatr. 6(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gossage L, Eisen T and Maher ER: VHL, the
story of a tumour suppressor gene. Nat Rev Cancer. 15:55–64.
2015.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Liu SJ, Wang JY, Peng SH, Li T, Ning XH,
Hong BA, Liu JY, Wu PJ, Zhou BW, Zhou JC, et al: Genotype and
phenotype correlation in von Hippel-Lindau disease based on
alteration of the HIF-α binding site in VHL protein. Genetics in
Medicine Official Journal of the American College of Medical
Genetics, 2018.
|
|
16
|
Liu Q, Yuan G, Tong D, Liu G, Yi Y, Zhang
J, Zhang Y, Wang LA, Wang L, Zhang D, et al: Novel
genotype-phenotype correlations in five Chinese families with Von
Hippel-Lindau disease. Endocr Connect. 7:870–878. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Smith ZL, Pietzak EJ, Meise CK, Van
Arsdalen K, Wein AJ, Malkowicz SB and Guzzo TJ: Simplification of
the Fuhrman grading system for renal cell carcinoma. Can J Urol.
22:8069–8073. 2015.PubMed/NCBI
|
|
18
|
Ben-Skowronek I and Kozaczuk S: Von
Hippel-Lindau Syndrome. Horm Res Paediatr. 84:145–152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chou A, Toon C, Pickett J and Gill AJ: von
Hippel-Lindau syndrome. Front Horm Res. 41:30–49. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arjumand W and Sultana S: Role of VHL gene
mutation in human renal cell carcinoma. Tumour Biol. 33:9–16.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tarade D and Ohh M: The HIF and other
quandaries in VHL disease. Oncogene. 37:139–147. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ordóñez-Navadijo Á, Fuertes-Yebra E,
Acosta-Iborra B, Balsa E, Elorza A, Aragonés J and Landazuri MO:
Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from
SART1-mediated degradation in clear-cell renal cell carcinoma.
Oncogene. 35:587–594. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Clifford SC, Cockman ME, Smallwood AC,
Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ and Maher ER:
Contrasting effects on HIF-1alpha regulation by disease-causing
pVHL mutations correlate with patterns of tumourigenesis in von
Hippel-Lindau disease. Hum Mol Genet. 10:1029–1038. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shuin T, Ashida S, Yao M and Kanno H: Von
Hippel-Lindau disease. Nihon Rinsho. 58:1448–1454. 2000.PubMed/NCBI(In Japanese).
|
|
25
|
Nordstrom-O'Brien M, van der Luijt RB, van
Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van
Brussel A, Voest EE and Giles RH: Genetic analysis of von
Hippel-Lindau disease. Hum Mutat. 31:521–537. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu SJ, Wang JY, Peng SH, Li T, Ning XH,
Hong BA, Liu JY, Wu PJ, Zhou BW, Zhou JC, et al: Genotype and
phenotype correlation in von Hippel-Lindau disease based on
alteration of the HIF-alpha binding site in VHL protein. Genet Med.
20:1266–1273. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Young RM and Simon MC: Untuning the tumor
metabolic machine: HIF-α: pro- and antitumorigenic? Nat Med.
18:1024–1025. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M
and Kaelin WG Jr: von Hippel-Lindau protein mutants linked to type
2C VHL disease preserve the ability to downregulate HIF. Hum Mol
Genet. 10:1019–1027. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Niemelä M, Lemeta S, Sainio M, Rauma S,
Pukkala E, Kere J, Böhling T, Laatikainen L, Jääskeläinen J and
Summanen P: Hemangioblastomas of the retina: Impact of von
Hippel-Lindau disease. Invest Ophthalmol Vis Sci. 41:1909–1915.
2000.PubMed/NCBI
|
|
30
|
González Escobar AB, Morillo Sánchez MJ
and García-Campos JM: Von Hippel-Lindau disease: Family study. Arch
Soc Esp Oftalmol. 87:368–372. 2012.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
|
31
|
Richard S, Gardie B, Couvé S and Gad S:
Von Hippel-Lindau: How a rare disease illuminates cancer biology.
Semin Cancer Biol. 23:26–37. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lefevre A, Mathis T, Denis P and Kodjikian
L: Retinal hemangioblastoma: Treatment strategy and long-term
follow-up in a retrospective cohort. J Fr Ophtalmol. 41:164–169.
2018.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
33
|
Woodward ER and Maher ER: Von
Hippel-Lindau disease and endocrine tumour susceptibility. Endocr
Relat Cancer. 13:415–425. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sovinz P, Urban C, Uhrig S, Stepan V,
Lackner H, Schwinger W, Benesch M, Moser A, Spuller E and Speicher
MR: Pheochromocytoma in a 2.75-year-old-girl with a germline von
Hippel-Lindau mutation Q164R. Am J Med Genet A. 152A:1752–1755.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Colvin A, Saltzman AF, Walker J, Bruny J
and Cost NG: Metastatic pheochromocytoma in an asymptomatic
12-Year-Old with von Hippel-Lindau disease. Urology. 119:140–142.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Petr EJ and Else T: Genetic predisposition
to endocrine tumors: diagnosis, surveillance and challenges in
care. Semin Oncol. 43:582–590. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lenders JW, Duh Q-Y, Eisenhofer G,
Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K and
Young WF Jr: Endocrine Society. Pheochromocytoma and paraganglioma:
An endocrine society clinical practice guideline. J Clin Endocrinol
Metab. 99:1915–1942. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tirosh A, Sadowski SM, Linehan WM, Libutti
SK, Patel D, Nilubol N and Kebebew E: Association of VHL genotype
with pancreatic neuroendocrine tumor phenotype in patients with von
Hippel-Lindau disease. JAMA Oncol. 4:124–126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Krauss T, Ferrara AM, Links TP, Wellner U,
Bancos I, Kvachenyuk A, Villar Gómez de Las Heras K, Yukina MY,
Petrov R, Bullivant G, et al: Preventive medicine of von
Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Endocr Relat Cancer. 25:783–793. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang J-Y, Peng S-H, Li T, Ning XH, Liu SJ,
Hong BA, Liu JY, Wu PJ, Zhou BW, Zhou JC, et al: Risk factors for
survival in patients with von Hippel-Lindau disease. J Med Genet.
55:322–328. 2018.PubMed/NCBI View Article : Google Scholar
|
